Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

In vitroandin vivoeffects of zoledronate on senescence and senescence-associated secretory phenotype markers

Samakkarnthai P. et al, (2023)

Clinical Guidelines on Paget's Disease of Bone.

Ralston SH. et al, (2019), J bone miner res, 34, 2327 - 2329

Drugs for the treatment of metabolic bone diseases.

Drake MT. et al, (2019), Br j clin pharmacol, 85, 1049 - 1051

Pharmacology of bisphosphonates.

Cremers S. et al, (2019), Br j clin pharmacol, 85, 1052 - 1062

Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline.

Ralston SH. et al, (2019), J bone miner res, 34, 579 - 604

Functional Characterization of a GGPPS Variant Identified in Atypical Femoral Fracture Patients and Delineation of the Role of GGPPS in Bone-Relevant Cell Types.

Roca-Ayats N. et al, (2018), J bone miner res, 33, 2091 - 2098

Pharmacokinetic Models for Bisphosphonate-Conjugated Drugs

Shah J. et al, (2018), Journal of bone and mineral research, 33, 178 - 178

A GGPS1 mutation found by WES in three sisters with bisphosphonate-associated atypical femoral fractures

Roca-Ayats N. et al, (2018), European journal of human genetics, 26, 679 - 679

Bone targeted bisphosphonate-antibiotic conjugates for the treatment of osteomyelitis biofilms.

Sedghizadeh P. et al, (2017), Journal of bone and mineral research, 32, S285 - S285

Functional Effects of the p.Asp188Tyr Mutation in the Geranylgeranyl Diphosphate Synthase (GGPS1) Gene Associated with Bisphosphonate-related Atypical Femoral Fractures.

Roca-Ayats N. et al, (2017), Journal of bone and mineral research, 32, S321 - S322

The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate).

Lawson MA. et al, (2017), J bone miner res, 32, 1860 - 1869

GGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates.

Roca-Ayats N. et al, (2017), N engl j med, 376, 1794 - 1795

Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate-Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms.

Sedghizadeh PP. et al, (2017), J med chem, 60, 2326 - 2343

Developments in the synthesis of new functionalized bisphosphonate drug candidates such as cyclic prodrugs

Pavlov VA. et al, (2016), Phosphorus, sulfur, and silicon and the related elements, 191, 1504 - 1508

Ignac Fogelman: 1948-2016.

Compston J. et al, (2016), J bone miner res, 31, 1785 - 1786

Marion David Francis: 1923-2016.

Ebetino FH. et al, (2016), J bone miner res, 31, 1783 - 1784

Pyrophosphate: a key inhibitor of mineralisation.

Orriss IR. et al, (2016), Curr opin pharmacol, 28, 57 - 68

Zoledronate Attenuates Accumulation of DNA Damage in Mesenchymal Stem Cells and Protects Their Function.

Misra J. et al, (2016), Stem cells, 34, 756 - 767

Fluorescent Bisphosphonate and Carboxyphosphonate Probes: A Versatile Imaging Toolkit for Applications in Bone Biology and Biomedicine.

Sun S. et al, (2016), Bioconjug chem, 27, 329 - 340

The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants.

Tsoumpra MK. et al, (2015), Bone, 81, 478 - 486

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?